Vanda Pharmaceuticals Inc. 8-K

What Happened

• On May 6, 2026 Vanda Pharmaceuticals Inc. announced and released a press release and held a conference call regarding its results of operations and financial condition for the quarter ended March 31, 2026. The press release is furnished with the Form 8-K as Exhibit 99.1. The company indicated that statements made during the earnings call include forward‑looking statements about its commercial products, pipeline, clinical and regulatory timelines, and commercial potential.

Key Details

• Filing date: May 6, 2026; reporting period: quarter ended March 31, 2026.
• Press release furnished as Exhibit 99.1 to the Form 8-K.
• Company warned that remarks on the call are forward‑looking and should be read with Vanda’s risk disclosures in its most recent Form 10‑K and subsequent 10‑Qs/8‑Ks.
• Form 8-K signed by Kevin Moran, Senior Vice President, Chief Financial Officer and Treasurer.

Why It Matters

• This filing signals Vanda has publicly released its quarterly results and commentary; investors should review the press release and listen to the earnings call for actual revenue, earnings, and operational details.
• The forward‑looking statements caution reminds investors to consider Vanda’s disclosed risks and prior SEC filings when evaluating any guidance or projections made on the call.